Finished product reference
Igm-enriched Human (Immune Globulin)
Injection · Parenteral · 50 mg/1mL · 50 mL
- List code
- 51997
- Pharmacologic class
- Blood product: IgM-enriched human immunoglobulin (intravenous)
What it is and how it works
A preparation of human plasma immunoglobulins enriched in IgM (with IgA and IgG). IgM is a potent activator of complement and an effective agglutinating and opsonising antibody, and the preparation provides antibodies that neutralise bacterial toxins and enhance clearance of pathogens.
Indications
Adjunctive treatment, with antibiotics, of severe bacterial infections and sepsis; replacement therapy in immunocompromised patients and severe secondary antibody deficiency.
Dosage and administration (summary)
Dosing is individualised by the specialist, given as an intravenous infusion over several days according to the product protocol and clinical response.
Contraindications
Hypersensitivity to human immunoglobulins, especially in IgA-deficient patients with antibodies against IgA; hereditary fructose intolerance if the product contains sorbitol or fructose.
Warnings and precautions
Infuse slowly initially and monitor for infusion and anaphylactic reactions. As with other intravenous immunoglobulins, thromboembolism, acute renal dysfunction, haemolysis and aseptic meningitis may occur; ensure adequate hydration. Derived from human plasma, so transmission of infectious agents cannot be totally excluded.
Pregnancy
Clinical experience with immunoglobulins suggests no harmful effects, but use only when clearly needed.
Storage and supply
Store at 2–8 °C; do not freeze; protect from light.
Source: reference summary prepared from the EU SmPC/EPAR, BNF and WHO Model Formulary. The approved product information in Iran governs.
Other presentations of the same active ingredient
Reference information for professional sourcing and registration enquiries, not medical advice or a promotion. Drug information is condensed from US FDA prescribing information (public domain, via openFDA and DailyMed) and does not replace the product’s approved labelling in Iran. Availability, origin and documentation are confirmed per enquiry.
Tell us the quantity, the market and the timing.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.